AGP & DTx Summit Advances Diabetes Care
Analysis based on 6 articles · First reported Jun 04, 2026 · Last updated Jun 04, 2026
The advancements in continuous glucose monitoring (CGM) and digital therapeutics (DTx) presented at the summit are expected to positively impact companies in the healthcare and medical device industries, particularly those involved in diabetes management. The demonstrated HbA1c reduction by DTx could lead to increased adoption and investment in these technologies, benefiting companies like Sibionics.
The 4th AGP & DTx Summit, co-organized by Sibionics, successfully concluded in Shenzhen, China, in May 2026. The summit focused on moving diabetes care 'Beyond Glucose' by translating CGM data into clinical insights and behavior change. Experts like Prof. Andrej Janež, Prof. Sofianos Andrikopoulos, Prof. Li Qiang, Prof. Shannon Lin, and Prof. Xiao Luo presented research on CGM and digital therapeutics (DTx), highlighting their role in personalized care, metabolic phenotyping, and AI integration. Evidence showed DTx was associated with a 0.54 percentage point HbA1c reduction. Patient representative Tom Vesely emphasized the goal of 'Time in Happiness' for diabetes management. The discussions underscored a shift in diabetes care from mere monitoring to active, data-driven intervention and change.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard